Belinda M. Juran


Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

Juran, Belinda M.

Belinda Juran's practice focuses on advising clients on technology-centered transactions. She helps biotechnology, pharmaceutical, medical device, high technology and service companies achieve their strategic goals by advising them on all phases of their product development and commercialization relationships. Ms. Juran negotiates and advises clients on collaboration, development, distribution, license and service agreements with customers, suppliers, licensors, licensees and other third parties, and on the acquisition and sale of intellectual property and joint venture arrangements. She works with clients on matters ranging from bet-the-company billion-dollar global strategic collaborations to day-to-day issues. Ms. Juran also has provided general corporate advice to public and private companies and has represented companies in venture capital financings, initial public offerings and mergers and acquisitions. She also works closely with WilmerHale's IP litigation team, negotiating settlement and license agreements to settle ANDA and other litigation matters.

Ms. Juran provides her clients with practical insights by combining her experience and education in technology, business and law. Prior to practicing law, Ms. Juran worked in the high technology industry for several years, where she developed sophisticated computer-aided engineering software, then managed engineering departments. She has also been a consultant to several high technology companies.

Learn more about Ms. Juran's practice and how she can support your startup on

Honors & Awards

  • Selected by peers for inclusion in the 2018 edition of the Best Lawyers in America for her biotechnology law practice
  • Recommended in the 2016 and 2017 editions of The Legal 500 United States for her work in M&A/Corporate and Commercial; Media, Technology and Telecoms: Outsourcing and Transactions; and Healthcare: Life Sciences
  • Named a Life Sciences Star in the 2016-2017 editions of LMG Life Sciences for finance and transactional
  • Recognized by The Legal 500 United States in 2013 as "a fantastic collaborator" and "outstanding in licensing"
  • LMG Life Sciences selected the firm as winner of its “Canadian Impact Deals of the Year” in 2013 award for its representation of Enobia Pharma in the company's acquisition by Alexion Pharmaceuticals, Inc.
  • Named to the Women's Business Boston's Top 10 Corporate Lawyers list

Publications & News


March 14, 2018

WilmerHale Counsels Voyager Therapeutics in Global Strategic Collaboration with AbbVie

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, and AbbVie, a global biopharmaceutical company, announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

December 22, 2017

WilmerHale Advises Centurion in Acquisition by Medline

On December 7, 2017, Medline completed its acquisition of Centurion Medical Products, a Michigan-based medical supplies manufacturer. The company will continue to operate as a subsidiary of Medline.

November 29, 2017

WilmerHale Represents Akamai in Acquisition of Nominum

Akamai Technologies, Inc. announced the company completed its acquisition of Nominum, a provider of DNS-based security solutions supporting many of the world's leading carriers.

November 7, 2017

LMG Life Sciences 2017 Honors WilmerHale With Top Rankings

LMG Life Sciences has recognized WilmerHale among the nation's leading life sciences law firms in its 2017 rankings, citing the firm's Life Sciences Practice as “renowned for its range and multidisciplinary teams that counsel clients in technology, pharmaceutical and medical device companies as well as investment banks and venture capitalists.”

August 16, 2017

WilmerHale Lawyers Named Among the 2018 Best Lawyers in America®, Nine Recognized as Lawyers of the Year

Best Lawyers in America®—the oldest and most respected peer-review publication in the legal industry—recognizes 107 WilmerHale lawyers and names nine partners as Lawyers of the Year in its 24th edition.

July 24, 2017

WilmerHale Reps Emergent BioSolutions in $96M Acquisition of GlaxoSmithKline Anthrax Drug

Emergent BioSolutions announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million.

June 9, 2017

The Legal 500 United States 2017 Recognizes 125 WilmerHale Lawyers Across 28 Practice Areas

The Legal 500 United States has released its 2017 rankings, recommending 125 WilmerHale lawyers—including 12 who are named to its elite “Leading Lawyers” list and two on its “Next Generation Lawyers” list—and 28 practice areas in its 11th edition.

May 16, 2017

Finding a Way Through a Tight Deal Space

WilmerHale's Life Sciences Group Co-Chairs Belinda Juran and Stuart Falber share trends they are seeing in the life sciences industry regarding acquisitions and IPOs in an interview with Breaking Media's Above the Law.

December 28, 2016

WilmerHale Counsels Tokai Pharmaceuticals in Share Purchase Agreement with Otic Pharma

The WilmerHale deal team included Partners Hal Leibowitz, Stuart Falber, Belinda Juran, Bill Caporizzo and Amy Null; Counsel Michael Welhouse; Senior Associate Ryan Mitteness; and Associate Andrea Sorrentino.

December 23, 2016

WilmerHale Represents PerkinElmer in Selling Medical Imaging Business

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced its intent to sell its Medical Imaging business, a supplier of flat panel X-ray detectors that serve as components for industrial, medical and dental X-ray imaging systems, to Varian Medical Systems.

Recent Highlights

  • Has represented Infinity Pharmaceuticals in its significant collaborations, including Infinity’s broad drug discovery collaboration with Purdue and the restructuring of that relationship, and Infinity’s collaboration with Intellikine on PI3K and the restructuring of that relationship
  • Has represented Idenix Pharmaceuticals in its significant collaborations, including, most recently, the reversion of development-stage rights to Idenix through the restructuring of its almost decade-long relationship with Novartis, on which Ms. Juran has advised from its inception
  • Has represented Constellation Pharmaceuticals in several transactions, including its collaboration and option agreements with Genentech and its funding collaboration with The Leukemia & Lymphoma Society® for BET inhibitor
  • Has represented Synta Pharmaceuticals in several development and commercialization collaboration, including with Hoffman-La Roche for drugs to treat inflammatory diseases
  • Has represented The Medicines Company in several development and commercialization collaborations, including its acquisition of Recothrom® assets from Bristol Myers Squibb and their related collaboration
  • Represented Enobia Pharma in the negotiation of the earn-out provisions in its acquisition by Alexion Pharmaceuticals, which may entitle Enobia’s stockholders to up to $470 million in milestone payments in addition to the $610 million paid up-front in cash
  • Has represented Aciex Therapeutics in several transactions, including an ophthalmic collaboration with Portola Pharmaceuticals
  • Represented Montreal-based Bellus Health in several transactions, including the acquisition of rights to eprodisate by Celtic Therapeutics
  • Has represented Millennium Pharmaceuticals in several license and collaboration agreements
  • Has represented Cerulean Pharma in several drug development and licensing agreements
  • Represented Visterra in an antibody discovery collaboration with Pfizer
  • Represented Rhythmia Medical in several transactions, including the negotiation of earn-outs in its acquisition by Boston Scientific
  • Represented Cubist Pharmaceuticals in a license and supply agreement with Teva to settle ANDA litigation
  • Represented Durata Therapeutics in the acquisition of RaQualia’s Japanese rights to dalbavancin, a MRSA compound
  • Represented Somaxon Pharmaceuticals in settlement and licensing agreements to settle ANDA litigation

Professional Activities

Ms. Juran has participated in the M. Ellen Carpenter Financial Literacy Program conducted through the Boston Bar Association.

Community Activities

Ms. Juran sits on the board of directors of UTEC, the United Teen Equality Center of Lowell, Massachusetts. Through job training, education and social support, UTEC enables Lowell's most disconnected young people to trade violence and poverty for social and economic success.


Skip Navigation Links.


JD, cum laude, Harvard Law School, 1998

MBA, magna cum laude, Boston University, 1995

BS, Mathematics, summa cum laude, University of Scranton, 1981

Bar Admissions


Skip Navigation Links.